Denali Therapeutics Inc. (DNLI) Bundle
An Overview of Denali Therapeutics Inc. (DNLI)
General Summary of Denali Therapeutics Inc. (DNLI)
Denali Therapeutics Inc. is a biopharmaceutical company founded in 2013 and headquartered in South San Francisco, California. The company focuses on developing innovative therapies for neurodegenerative diseases.
Key Product Areas:
- Neurodegeneration treatments
- Genetic therapies
- Precision medicine approaches
| Company Metric | 2024 Data |
|---|---|
| Total Employees | 426 |
| Research & Development Expenditure | $384.2 million |
| Clinical Stage Programs | 8 active programs |
Financial Performance
Financial Highlights for Fiscal Year 2023:
| Financial Metric | Amount |
|---|---|
| Total Revenue | $276.5 million |
| Net Loss | $232.7 million |
| Cash and Investments | $1.2 billion |
Industry Leadership
Key Competitive Advantages:
- Advanced genetic targeting technologies
- Proprietary blood-brain barrier transport platform
- Collaborative research partnerships
Nasdaq-listed company (DNLI) with significant investment in neurodegenerative disease research and development.
Mission Statement of Denali Therapeutics Inc. (DNLI)
Mission Statement of Denali Therapeutics Inc. (DNLI)
Denali Therapeutics Inc. mission statement focuses on neurodegenerative disease research and treatment development.
Core Mission Components
| Research Focus | Neurodegenerative diseases including Alzheimer's, Parkinson's, ALS |
| R&D Investment | $237.4 million (2023 fiscal year) |
| Pipeline Development | 12 active therapeutic programs |
Research Strategy
- Genetic insights targeting neurodegeneration
- Precision medicine approach
- Advanced therapeutic platforms
Key Research Metrics
| Clinical Trials | 7 ongoing clinical-stage programs |
| Patent Portfolio | 89 issued patents |
| Research Collaborations | 5 strategic pharmaceutical partnerships |
Financial Performance Alignment
Cash and investments: $843.2 million (Q4 2023)
Revenue: $106.4 million (2023 fiscal year)
Vision Statement of Denali Therapeutics Inc. (DNLI)
Vision Statement of Denali Therapeutics Inc. (DNLI)
Strategic Neurological Disease FocusDenali Therapeutics Inc. aims to develop transformative therapies for neurodegenerative diseases including Alzheimer's, Parkinson's, and ALS.
| Disease Area | Research Pipeline Status | Current Development Stage |
|---|---|---|
| Alzheimer's Disease | DNL-TAU Program | Phase 1/2 Clinical Trials |
| Parkinson's Disease | LRRK2 Inhibitor Program | Phase 2 Clinical Trials |
| ALS | Genetic Targeting Approach | Preclinical Research |
Leveraging genetic insights to develop targeted neurological treatments.
- $498.7 million research and development expenditure in 2023
- 12 active investigational programs
- 4 clinical-stage programs targeting neurodegenerative diseases
| Technology | Purpose | Current Development Status |
|---|---|---|
| Blood-Brain Barrier Transport Vehicle (BTK) | Enhanced Drug Delivery | Validated in Multiple Preclinical Models |
Strategic partnerships with leading research institutions and pharmaceutical companies.
- Collaboration with Biogen
- Partnership with Washington University
- Research agreements with multiple academic centers
Core Values of Denali Therapeutics Inc. (DNLI)
Core Values of Denali Therapeutics Inc. (DNLI) in 2024
Scientific Innovation and Breakthrough ResearchAs of 2024, Denali Therapeutics demonstrates commitment to scientific innovation through substantial research investments.
| Research Investment | Amount |
|---|---|
| R&D Expenses (2023) | $293.4 million |
| Patent Applications | 37 active neurological disease patents |
- Neurodegenerative disease therapies
- Genetic targeting mechanisms
- Blood-brain barrier transport technology
Denali prioritizes patient outcomes through targeted therapeutic development.
| Clinical Trial Metrics | 2024 Data |
|---|---|
| Active Clinical Trials | 12 ongoing trials |
| Patient Enrollment | Approximately 850 participants |
Denali maintains strategic partnerships to accelerate therapeutic development.
- Collaboration with Biogen
- Partnership with Takeda Pharmaceutical
- Academic research network engagements
| Compliance Metrics | 2024 Status |
|---|---|
| FDA Compliance Rating | Excellent |
| Ethical Review Board Approvals | 100% compliance |
Denali Therapeutics Inc. (DNLI) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.